Press Release

Infographic | HitGen FY2021 Annual Report

CHENGDU, China, April 19, 2022 – HitGen Pharmaceuticals Inc. and the PACS1 Syndrome Research Foundation announce an agreement focused on the application of HitGen’s DNA-encoded library (DEL) technology to identify ligands that could selectively bind to the mutated PACS1 Protein and therefore serve as a treatment or a cure for patients with PACS1 Syndrome.

CHENGDU, China, April 6, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical company aiming for new drug development employing “Protein Degradation Technology”. During the collaboration, multiple undisclosed targets were screened against HitGen’s proprietary over 1 trillion DNA-encoded libraries (DELs). The majority of the targets have resulted in confirmed hits, which have high potential for PROTAC development. Now the two parties are extending the collaboration on further development of these projects and additional challenging targets.

In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.

Lipigon Pharmaceuticals AB ("Lipigon") and HitGen Inc. (“HitGen”) today announced that they have identified novel small molecules that could be starting points for developing drugs targeting dyslipidemia and cardiovascular disease.

CHENGDU, China, March 17, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Howard Hughes Medical Institute (“HHMI”) and Duke University. The Principal Investigators for HHMI and Duke University who will oversee the collaboration will be Dr. Robert J. Lefkowitz, a James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry at the Duke University Medical Center,

Chengdu, China, February 25, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (“MTPC”), a Japanese pharmaceutical company with the mission of “Creating hope for all facing illness”.

Chengdu, China December 23, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, and HitGen Inc. (”HitGen”) have extended the collaboration agreement on the development of small molecules for the treatment of dyslipidemia and cardiometabolic disease until 7 July 2024.

Chengdu, China, and Cambridge, United Kingdom, 5 November 2021 – HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.

Chengdu, China, 1 November 2021 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.